Long-term risks from prostate cancer treatment detailed in new report

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions.  Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login